Levodopa-induced dyskinesias in Parkinson's disease: Etiology, impact on quality of life, and treatments

European Neurology

Volumn 60, Issue 2, 2008, Pages 57-66

  Encarnacion, Elmyra V ^a   Hauser, Robert A ^b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Dyskinesia; Levodopa; Management; Parkinson's disease; Quality of life; Treatment

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BUSPIRONE; CARBIDOPA PLUS LEVODOPA; DEXTROMETHORPHAN; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ETIRACETAM; FLUOXETINE; IDAZOXAN; LEVODOPA; MIRTAZAPINE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TOLCAPONE; TOPIRAMATE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG EFFECT; DRUG HALF LIFE; DYSKINESIA; HUMAN; MONOTHERAPY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

AGED; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; CORPUS STRIATUM; DEEP BRAIN STIMULATION; DOPAMINE; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; LEVODOPA; MULTICENTER STUDIES AS TOPIC; PARKINSON DISEASE; QUALITY OF LIFE; RECEPTORS, GLUTAMATE; SEVERITY OF ILLNESS INDEX;

EID: 48349116255     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000131893     Document Type: Review

References (122)

1. Olanow W, Schapira AH, Rascol O: Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000;23:S117-S126.
2. Nutt JG, Obeso JA, Stocchi F: Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000;23:S109-S115.
3. Hauser RA, McDermott MP, Messing S, for the Parkinson Study Group: Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756-1760.
4. Koller WC, Tse W: Unmet medical needs in Parkinson's disease. Neurology 2004;62:S1-S8.
5. Thanvi BR, Lo TC: Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J 2004;80:452-458.
6. Chase TN: The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55:1-9.
7. Chase TN: Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50:S17-S25.
8. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW: The evolution and origin of motor complications in Parkinson's disease. Neurology 2000;55:S13-S20.
9. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW: Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 2000;47:S22-S32.
10. Oh JD, Russell DS, Vaughan CL, Chase TN: Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res 1998;813:150-159.
11. Schrag A, Quinn N: Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 2000;123:2297-2305.
12. Grandas F, Galiano ML, Tabernero C: Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999;246:1127-1133.
13. Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
14. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE: Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006;63:205-209.
15. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE: Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005;20:342-344.
16. Zach M, Friedman A, Slawek J, Derejko M: Quality of life in Polish patients with long-lasting Parkinson's disease. Mov Disord 2004;19:667-672.
17. Blanchet PJ, Allard P, Grégoire L, Tardif F, Bédard PJ: Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996;23:189-193.
18. The Parkinson Study Group: Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
19. Fahn S; the Parkinson Study Group: Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252:IV37-IV42.
20. Colosimo C, De Michele M: Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur J Neurol 1999;6:1-21.
21. Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group: The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004;18:733-746.
22. The Parkinson Study Group: Pramipexole versus levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
23. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE; for the 056 Study Group: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
24. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA: Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
25. Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, Hurtig H, Yahr M: A multicenter trial of ropinirole as adjunct treatment for parkinson's disease: ropinirole study group. Neurology 1998;51:1057-1062.
26. Olanow CW, Fahn S, Muenter MD, Klawans H, Hurtig H, Stern MB, Shoulson I, Kurlan R, Grimes JD, Jankovic J, Hoehn M, Markham CH, Duvoisin R, Reinmuth O, Leonard HA, Ahlskog E, Feldman R, Hershey L, Yahr M: A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
27. Brooks DJ, Sagar H; the UK-Irish Entacapone Study Group: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003;74:1071-1079.
28. Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J; for the US01 Study Team: Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004;61:1563-1568.
29. Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D, Pedder S: Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment: the Tolcapone Stable Study Group. Neurology 1997;49:665-671.
30. Quinn N: Drug treatment of Parkinson's disease. BMJ 1995;310:575-579.
31. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; The Parkinson Study Group: Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.
32. The Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-248.
33. Marras C, Lang AE: Measuring motor complications in clinical trials for early Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:143-146.
34. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease: The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-750.
35. Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I; the Parkinson Study Group: Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord 2002;17:758-763.
36. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 2001;58:1660-1668.
37. Guy W: ECDEU Assessment Manual for Psychopharmacology (Abnormal Involuntary Movement Scale [AIMS]). Rockville, National Institute of Mental Health, 1976, pp 534-537.
38. Stocchi F, Ruggieri S, Vacca L, Olanow CW: Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125:2058-2066.
39. Stocchi F, Vacca L, Ruggieri S, Olanow CW: Intermittent versus continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
40. Goetz CG, Stebbins GT, Shale HM, Lang AE, Chernik DA, Chmura TA, Ahlskog JE, Dorflinger EE: Utility of an objective dyskinesia rating scale for Parkinson's disease: interand intrarater reliability assessment. Mov Disord 1994;9:390-394.
41. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, Molho ES, Factor SA: A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
42. Hauser RA, Deckers F, Lehert P: Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord 2004;19:1409-1413.
43. Karlsen KH, Larsen JP, Tandberg E, Maeland JG: Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:431-435.
44. Gage H, Hendricks A, Zhang S, Kazis L: The relative health related quality of life of veterans with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:163-169.
45. Schrag A, Selai C, Jahanshahi M, Quinn NP: The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:67-73.
46. Karlsen KH, Tandberg E, Arsland D, Larsen JP: Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000;69:584-589.
47. Pechevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M; on behalf of the Trial Study Group: Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005;12:956-963.
48. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F: Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-230.
49. Damiano AM, McGrath MM, Willian MK, Snyder CF, LeWitt PA, Reyes PF, Richter RR, Means ED: Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 2000;9:87-100.
50. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE: Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17.
51. Colzi A, Turner K, Lees AJ: Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
52. Ashburn A, Stack E, Pickering RM, Ward CD: A community-dwelling sample of people with Parkinson's disease: characteristics of fallers and non-fallers. Age Ageing 2001;30:47-52.
53. Kempster PA, Wahlqvist ML: Dietary factors in the management of Parkinson's disease. Nutr Rev 1994;52:51-58.
54. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G; the Parkinson Study Group: Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 2004;19:22-28.
55. Hely MA, Morris JGL, Reid WGJ, Trafficante R: Sydney Multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
56. Hiner BC, Earnhart M: Ropinirole as compared with levodopa in Parkinson's disease. N Engl J Med 2000;343:884.
57. Dodel RC, Berger K, Oertel WH: Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001;19:1013-1038.
58. Blanchet PJ, Calon F, Morissette M, Goulet M, Grondin R, Levesque D, Bedard PJ, Di Paolo T: Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model. Adv Neurol 2001;86:337-344.
59. Pearce RK, Banerji T, Jenner P, Marsden CD: De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998;13:234-241.
60. Maratos EC, Jackson MJ, Pearce RK, Jenner P: Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 2001;16:631-641.
61. Parkinson Study Group: Pramipexole versus levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
62. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M; the 056 Study Group: Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006;21:1844-1850.
63. Hely MA, Morris JG, Reid WG, O'Sullivan DJ, Williamson PM, Rail D, Broe GA, Margrie S: The Sydney Multicentre Study of Parkinson's Disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-910.
64. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y; on behalf of the Parkinson's Disease Research Group of the United Kingdom: Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001;57:1687-1694.
65. Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, Schwarz J: Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 2006;21:343-353.
66. Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 2007;22:1317-1319.
67. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammerstad JP, Gordin A: Effect of peripheral catechol- O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
68. Jenner P: Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62:S47-S55.
69. Marin C, Aguilar E, Obeso JA: Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. Mov Disord 2006;21:646-653.
70. Koller WC, Hutton JT, Tolosa E, Capilldeo R; the Carbidopa/Levodopa Study Group: Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999;53:1012-1019.
71. Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW: Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 1993;43:1036-1039.
72. Nirenberg MJ, Fahn S: The role of levodopa and catechol-o- methyltransferase inhibitors; in Schapira AHV, Olanow CW (eds): Principles of Treatment in Parkinson's Disease. Philadelphia, Butterworth Heinemann Elsevier, 2005, pp 3-16.
73. Obeso JA, Rodriguez-Oroz MC, Zamarbide I: Clinical features, pathophysiology, and management of motor complications in Parkinson's disease; in Schapira AHV, Olanow CW (eds): Principles of Treatment in Parkinson's Disease. Philadelphia, Butterworth Heinemann Elsevier, 2005, pp 99-112.
74. Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C, Aquilonius SM: Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-163.
75. Nyholm D, Nilsson Remahl AIM, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius S-M, Askmark H: Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
76. Mouradian MM, Heuser IJ, Baronti F, Chase TN: Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
77. Nilsson D, Hansson LE, Johansson K, Nystrom C, Paalzow L, Aquilonius SM: Longterm intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998;97:175-183.
78. Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, Langston JW: Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993;43:1698-1703.
79. Obeso JA, Grandas F, Vaamonde J, Rosario LM, Martinez-Lage JM: Apomorphine infusion for motor fluctuations in Parkinson's disease. Lancet 1987;1:1376-1377.
80. Pollak P, Champay AS, Hommel M, Perret JE, Benabid AL: Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:544.
81. Frankel JP, Lees AJ, Kempster PA, Stern GM: Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
82. Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L: Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease: long-term follow-up in 18 patients. Adv Neurol 1993;60:656-659.
83. Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, Stern GM: Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-170.
84. Pietz K, Hagell P, Odin P: Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65:709-716.
85. Snow BJ, Macdonald L, Mcauley D, Wallis W: The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23:82-85.
86. da Silva-Junior FP, Braga-Neto P, Sueli Monte F, de Bruin VM: Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Related Disord 2005;11:449-452.
87. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M: Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:141-143.
88. Paci C, Thomas A, Onofrj M: Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol Sci 2001;22:75-76.
89. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U: Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001;16:515-520.
90. Luginger E, Wenning GK, Bosch S, Poewe W: Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:873-878.
91. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN: Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999;56:1383-1386.
92. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
93. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O: Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004;62:381-388.
94. Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, Scoppetta C: Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand 1998;97:295-299.
95. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ: Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995.
96. Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natte R, Chase TN: A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 1998;13:414-417.
97. Metman LV, Del Dotto P, Natte R, van den Munckhof P, Chase TN: Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998;51:203-206.
98. Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM: Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord 2005;20:403-409.
99. Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA: Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2005;20:1205-1209.
100. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G: Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994;17:73-82.
101. Kleedorfer B, Lees AJ, Stern GM: Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 1991;54:376-377.
102. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y: Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995;45:1855-1858.
103. Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, Agid Y: Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 2001;16:708-713.
104. Meco G, Fabrizio E, Di Rezze S, Alessandri A, Pratesi L: Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 2003;26:179-181.
105. Jenner P: Istradefylline, a novel adenosine A 2A receptor antagonist, for the treatment of Parkinson's disease. Exp Opin Invest Drugs 2005;14:729-738.
106. Hauser RA, Hubble JP, Truong DD, and the Istradefylline US-001 Study Group: Randomized trial of the adenosine A 2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.
107. 2A receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-296.
108. 1A agonist in advanced Parkinson's disease. Mov Disord 2005;20:932-936.
109. Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H: Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004;27:58-62.
110. 1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease [in Japanese]. No To Shinkei 2002;54:133-137.
111. DeLong MR: Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
112. McIntyre CC, Savasta M, Walter BL, Vitek JL: How does deep brain stimulation work? Present understanding and future questions. J Clin Neurophysiol 2004;21:40-50.
113. Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammerstad JP: Pallidal versus subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol 2005;62:554-560.
114. Ford B, Winfield L, Pullman SL, Frucht SJ, Du Y, Greene P, Cheringal JH, Yu Q, Cote LJ, Fahn S, McKhann GM II, Goodman RR: Subthalamic nucleus stimulation in advanced Parkinson's disease: blinded assessments at one year follow up. J Neurol Neurosurg Psychiatry 2004;75:1255-1259.
115. Ostergaard K, Sunde N, Dupont E: Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord 2002;17:693-700.
116. Ostergaard K, Aa Sunde N: Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus. Mov Disord 2006;21:624-631.
117. Rodriguez-Oroz MC, Zamarbide I, Guridi J, Palmero MR, Obeso JA: Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation. J Neurol Neurosurg Psychiatry 2004;75:1382-1385.
118. Visser-Vandewalle V, van der Linden C, Temel Y, Celik H, Ackermans L, Spincemaille G, Caemaert J: Long-term effects of bilateral subthalamic nucleus stimulation in advanced Parkinson disease: a four year follow-up study. Parkinsonism Related Disord 2005;11:157-165.
119. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid A-L, Pollak P: Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-1934.
120. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, Daniels C, Deutschlander A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider G-H, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J; for the German Parkinson Study Group, Neurostimulation Section: A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
121. Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A: Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 1999;53:85-90.
122. Vingerhoets FJG, Villemure J-G, Temperli P, Pollo C, Pralong E, Ghika J: Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 2002;58:396-401.